Given that low-grade inflammation is implicated in the pathophysiology of age-related frailty, we tested the hypothesis that individual blood biomarkers are associated with the risk of developing frailty in later life. Participants of the ATTICA cohort aged ≥33 years in 2002 were assessed for age-related frailty in 2024. By multivariable logistic regression models, we tested the association of an array of baseline immune-related biomarkers, as well as of an aggregate score, namely ImmActScore, that combines IL-6, TNF-α and fibrinogen, on the odds of later-life frailty. Among 574 participants (mean baseline age 48±8; 50% male), phenotypic FRAIL scale assessment categorized 6% as frail, 29% as prefrail, and 65% as robust. After adjustments for various socio-demographic and clinical characteristics, baseline fibrinogen (OR=1.004, 95%CI:1.000-1.007, p=0.037) and ImmActScore (OR=1.239, 95%CI:1.007-1.525, p=0.042) showed significant associations, suggesting that higher baseline levels are associated with increased odds for prefrailty/frailty in the very long-term. Fibrinogen and a composite score capturing immune activation status by combining IL-6, TNF-α and fibrinogen, were both associated with the odds of prefrailty/frailty after 22 years. Further studies are warranted to confirm whether assessing immune-related biomarkers in middle-age may help identify individuals with a higher likelihood of frailty. • Higher baseline fibrinogen is associated with pre-frailty/frailty after 22 years • Increasing ImmActScore (IL-6/TNF-α/fibrinogen) associates with pre-frailty/frailty • A more activated immune system may predispose to inflammaging-related frailty
Giannakopoulou et al. (Sun,) studied this question.